Once-daily oral ICP-332 results in large reduction in eczema scores and shows favorable safety in adults with moderate-to-severe atopic dermatitis.

The paper, titled, "Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study," was published in Obesity, the peer-reviewed ...

Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH ...

AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company pioneering therapies for inherited retinal diseases (IRDs), has announced the completion of enrollment in LUCE-1, their Phase 1/2 ...

Clarametyx today announced positive topline data from a Phase 1b/2a trial evaluating its novel antibody therapy, CMTX-101, in cystic fibrosis (CF).

MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase ...

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for ...

MapLight Therapeutics, Inc. (MapLight) (Nasdaq: MPLT) today announced an update to the expected timing of topline results for its ongoing Phase 2 ZEPHYR and IRIS clinical studies, which are ...

Energy Fuels recently reported that it exceeded its 2025 uranium production, mined ore, and uranium concentrate sales ...

Sanofi's amlitelimab has shown promise in the Phase III COAST 1 trial, but data from the COAST 2 study is yet to be announced ...

An extension study of Amgen's experimental obesity drug MariTide found that it helped people maintain weight loss when given ...